Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole 40 mg for remission of non-erosive and erosive gastroesophageal reflux disease
2004-004806-25Phase 3Completed
- Sponsor
- Altana Pharma
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of pantoprazole in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE), sponsored by Altana Pharma. Primary endpoint: Complete reflux disease remission rate at 8 weeks. Started Mar 2005; status: completed.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on 2004-004806-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004806-25.